Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
A human subjects research study, the primary purpose of which is to assess the EFFECTS OF
SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2
DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The
study will randomize subjects with diabetes to either semaglutide or matching placebo.
Magnetic resonance images will be primary endpoint measured at baseline and at one year to
assess effect of this FDA approved medication.
Given the available evidence supporting the neuroprotective effect of this drug class and
stroke reduction with semaglutide, and our preliminary data showing that T2D had
significantly reduced total number of distal arterial branches in the brain than non-T2D, we
expect treatment with semaglutide will be associated with improved intracranial blood flow
condition.